292 related articles for article (PubMed ID: 30999307)
21. [Salt-induced inappropriate augmentation of intrarenal RAAS and its treatment in patients with chronic kidney disease].
Konishi Y
Nihon Rinsho; 2012 Sep; 70(9):1588-92. PubMed ID: 23012808
[TBL] [Abstract][Full Text] [Related]
22. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
Alfie J; Aparicio LS; Waisman GD
Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
[TBL] [Abstract][Full Text] [Related]
23. Renin-angiotensin-aldosterone system inhibitors in heart failure.
Shearer F; Lang CC; Struthers AD
Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
[TBL] [Abstract][Full Text] [Related]
24. Novel aspects of the renin-angiotensin-aldosterone-system.
Wolf G
Front Biosci; 2008 May; 13():4993-5005. PubMed ID: 18508564
[TBL] [Abstract][Full Text] [Related]
25. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
[TBL] [Abstract][Full Text] [Related]
26. [Role of RAAS inhibitors for the treatment of heart failure].
Murohara T
Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
[TBL] [Abstract][Full Text] [Related]
27. [The participation of the renin-angiotensin-aldosterone system in the pathogenesis of acute kidney failure in endotoxemia].
Krishtal' NV; Frolov AF; Kukharchuk AL
Lik Sprava; 1995; (3-4):92-4. PubMed ID: 8819932
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of RAAS--when is it too much?
Navarro P; Moskowitz R; Le Jemtel TH
Curr Heart Fail Rep; 2004 Jul; 1(2):57-64. PubMed ID: 16036026
[TBL] [Abstract][Full Text] [Related]
29. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink.
Scott J; Jones T; Redaniel MT; May MT; Ben-Shlomo Y; Caskey F
BMC Nephrol; 2019 Dec; 20(1):481. PubMed ID: 31888533
[TBL] [Abstract][Full Text] [Related]
30. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.
Brown J; de Boer IH; Robinson-Cohen C; Siscovick DS; Kestenbaum B; Allison M; Vaidya A
J Clin Endocrinol Metab; 2015 Feb; 100(2):490-9. PubMed ID: 25412416
[TBL] [Abstract][Full Text] [Related]
31. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
Onuigbo MA
Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
[TBL] [Abstract][Full Text] [Related]
32. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
33. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
Ryan MJ; Tuttle KR
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
[TBL] [Abstract][Full Text] [Related]
34. The renin-angiotensin-aldosterone system: approaches to cardiac and renal therapy.
Otte M; Spier A
Compend Contin Educ Vet; 2009 Jan; 31(1):E1-7; quiz E7. PubMed ID: 19241351
[TBL] [Abstract][Full Text] [Related]
35. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
36. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice.
Auron M; Harte B; Kumar A; Michota F
Postgrad Med J; 2011 Jul; 87(1029):472-81. PubMed ID: 21441164
[TBL] [Abstract][Full Text] [Related]
37. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
Nehme A; Zibara K
Hypertens Res; 2017 Nov; 40(11):903-909. PubMed ID: 28680167
[TBL] [Abstract][Full Text] [Related]
38. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
Khatib R; Joseph P; Briel M; Yusuf S; Healey J
Int J Cardiol; 2013 Apr; 165(1):17-24. PubMed ID: 22421406
[TBL] [Abstract][Full Text] [Related]
39. Key developments in renin-angiotensin-aldosterone system inhibition.
Sevá Pessôa B; van der Lubbe N; Verdonk K; Roks AJ; Hoorn EJ; Danser AH
Nat Rev Nephrol; 2013 Jan; 9(1):26-36. PubMed ID: 23165302
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
Pende A; Montecucco F
Curr Pharm Des; 2012; 18(7):950-1. PubMed ID: 22283769
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
